Reblozyl
Total Payments
$481,252
Transactions
1,814
Doctors
1,167
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2021 | $124,355 | 1,191 | 852 |
| 2020 | $174,518 | 457 | 351 |
| 2019 | $182,379 | 166 | 129 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $270,232 | 81 | 56.2% |
| Unspecified | $179,379 | 35 | 37.3% |
| Food and Beverage | $29,054 | 1,674 | 6.0% |
| Space rental or facility fees (teaching hospital only) | $1,000 | 1 | 0.2% |
| Travel and Lodging | $907.38 | 6 | 0.2% |
| Education | $680.00 | 17 | 0.1% |
Payments by Type
General
$301,873
1,779 transactions
Research
$179,379
35 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase-2 Study To Determine Efficacy and Safety of Luspatercept in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia With or Without Red Blood Cell-Transfusion Dependence (ACE-536-MF-001) | Celgene Corporation | $78,418 | 7 |
| A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alpha for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Due to Myelodysplastic Syndrome (MDS) ESA in Native Subjects Who Require Red Blood Cell Transfusions (ACE-536-MDS-002) | Celgene Corporation | $55,710 | 0 |
| A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MEDALIST) (ACE-536-MDS-001) | Celgene Corporation | $35,648 | 7 |
| A Phase 3, Double-Blind, Placebo Controlled Multicenter Study to Determine the Efficacy and Safety of Luspatercept (ACE-536) in Adults With Transfusion Dependent Beta (B)-Thalassemia (ACE-536-B-THAL-001) | Celgene Corporation | $9,603 | 1 |
Top Doctors Receiving Payments for Reblozyl
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Chicago, IL | $154,914 | 21 |
| , M.D | Hematology | Cincinnati, OH | $13,363 | 2 |
| , M.D | Hematology & Oncology | Boston, MA | $12,575 | 3 |
| , MD | Pediatric Hematology-Oncology | Memphis, TN | $12,238 | 2 |
| , M.D | Hematology & Oncology | La Mesa, CA | $9,610 | 4 |
| , MD | Hematology & Oncology | Orlando, FL | $9,480 | 3 |
| , M.D | Pediatric Hematology-Oncology | Los Angeles, CA | $9,480 | 3 |
| , M.D | Student in an Organized Health Care Education/Training Program | Los Angeles, CA | $8,903 | 6 |
| , M.D | Hematology & Oncology | Tamarac, FL | $7,430 | 5 |
| , MD | Medical Oncology | Dallas, TX | $7,250 | 2 |
| , MD | Medical Oncology | Waterloo, IA | $7,250 | 3 |
| , M.D | Cytopathology | Aurora, CO | $7,040 | 1 |
| , MD | Hematology & Oncology | Philadelphia, PA | $7,010 | 4 |
| , M.D | Hematology | Los Angeles, CA | $6,819 | 6 |
| , M.D | Hematology & Oncology | Los Angeles, CA | $6,791 | 6 |
| , MD | Hematology & Oncology | New York, NY | $6,410 | 2 |
| , M.D | Medical Oncology | Houston, TX | $6,223 | 2 |
| , M.D | Hematology & Oncology | Pittsburgh, PA | $6,195 | 3 |
| Sujit Sheth | Pediatric Hematology-Oncology | New York, NY | $5,940 | 2 |
| , MD | Anatomic Pathology & Clinical Pathology | Saint Louis, MO | $5,490 | 1 |
| , MD | Hematology | Dallas, TX | $5,490 | 1 |
| , MD, PHD | Anatomic Pathology & Clinical Pathology | Minneapolis, MN | $5,490 | 1 |
| Govind Bhagat | Hematology | New York, NY | $5,490 | 1 |
| , MD | Internal Medicine | Seattle, WA | $4,760 | 2 |
| , M.D | Hematology & Oncology | Houston, TX | $4,495 | 2 |
Ad
Manufacturing Companies
- Acceleron Pharma, Inc. $298,873
- Celgene Corporation $182,379
Product Information
- Type Drug
- Total Payments $481,252
- Total Doctors 1,167
- Transactions 1,814
About Reblozyl
Reblozyl is a drug associated with $481,252 in payments to 1,167 healthcare providers, recorded across 1,814 transactions in the CMS Open Payments database. The primary manufacturer is Acceleron Pharma, Inc..
Payment data is available from 2019 to 2021. In 2021, $124,355 was paid across 1,191 transactions to 852 doctors.
The most common payment nature for Reblozyl is "Consulting Fee" ($270,232, 56.2% of total).
Reblozyl is associated with 4 research studies, including "A Phase-2 Study To Determine Efficacy and Safety of Luspatercept in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia With or Without Red Blood Cell-Transfusion Dependence (ACE-536-MF-001)" ($78,418).